Experimental HIV Drugs
Experimental HIV Drugs
IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study
- Details
- Category: Experimental HIV Drugs
- Published on Sunday, 11 October 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.
Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 October 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.
Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.
10/6/15
IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 27 July 2015 00:00
- Written by Liz Highleyman
People who switch from the current version of tenofovir (TDF) to tenofovir alafenamide (TAF) -- a new formulation that reaches higher levels in HIV-infected cells -- maintained undetectable viral load and saw improvements in kidney function biomarkers and bone density, according to a pair of studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver.
Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 02 September 2015 00:00
- Written by Gilead Sciences
A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.
IAS 2015: New NNRTI Doravirine Suppresses HIV as Well as Efavirenz But with Fewer CNS Side Effects
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 23 July 2015 00:00
- Written by Liz Highleyman
Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related adverse events -- in particular central nervous system (CNS) side effects -- and were less likely to stop treatment prematurely, according to study findings reported this week at the at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.
More Articles...
- IAS 2015: Maturation Inhibitor BMS-955176 Shows Good Antiviral Activity with Atazanavir
- Gilead Requests FDA Approval of Tenofovir Alafenamide Single-Tablet Regimen
- Gilead Requests Approval of Tenofovir Alafenamide Dual Combination Pill
- CROI 2015: Cabotegravir and Rilpivirine Effective for HIV Maintenance Therapy at 96 Weeks
Web Design and Development by